Highlights and key takeaways from the 2026 EPA Congress

Professor Meryam Schouler-Ocak provides an expert overview of the most impactful discussions, clinical updates, and essential takeaways from the 2026 EPA Congress, exploring the latest advancements and future directions in psychiatric research and practice.

The importance of early detection and diagnosis of dementia

We asked Professor Rebecca Edelmayer, Vice President of Scientific Engagement at the Alzheimer's Association about important news about the diagnosis and treatment of dementia at AAIC 2025. Important Websites ALZPro -- Your central hub offering the latest clinical guidelines, education and training, research publications and practical tools for researchers, clinicians and dementia care providers. Built to empower all dementia professionals, ALZPro delivers timely, relevant resources to advance evidence-informed, person-centered care. https://pro.alz.org/ ALZ-NET -- Collects clinical and safety data about patients being evaluated for memory concerns or receiving new FDA-approved treatments for Alzheimer’s disease, including drugs/medications and devices, and tracks the long-term health outcomes associated with their use in real-world settings. ALZ-NET is a voluntary health care provider-enrolled patient network. https://www.alz-net.org/ U.S. POINTER -- A clinical trial to evaluate whether lifestyle interventions that simultaneously target multiple risk factors protect cognitive function in older adults (age 60-79) at increased risk for cognitive decline. It is the first such study to be conducted in a large group of U.S. residents. https://www.alz.org/us-pointer/home.asp https://www.alz.org/us-pointer/study-results.asp AAIC 2026 -- London https://aaic.alz.org/

Why there is no such thing as a psychiatric diagnosis?

Sami Timimi indicated in his presentation at the RCPsych in Scotland Winter Conference that formal psychiatric diagnostic systems should be abolished. In our interview  he  explains why psychiatric labels do more harm than good.

Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis

Edoardo Ostinelli, Senior Researcher & Deputy Lead of Oxford Precision Psychiatry Lab at the Department of Psychiatry, University of Oxford, UK. He is the first author of a recently published article in Lancet Psychiatry about ADHD in adults. How important is this question? How many patients suffer from the disease? We asked him about the study.

Social cognition in autism and ADHD

Sven Bölte, professor of child and adolescent psychiatric science at Karolinska Institute, Stockholm, Sweden, renowned expert of neurodevelopmental disorders. He is the first author of a recently published article in Neuroscience & Biobehavioral Reviews about social cognition in autism and ADHD. We asked him about the study. ⁠Article: Social cognition in autism and ADHD⁠

Addressing Comorbid Bipolar Disorder and ADHD

Mark Jankelow, MSN, PMHNP-BC summarizes his presentation at Real Psychiatry 2025 on bipolar disorder and ADHD and shares his 20 years of experience with treatments.

Current issues in the treatment of schizophrenia

Professor Istvan Bitter from Semmelweis University, Budapest, Hungary is sharing his insights on schizophrenia treatment. In the last decades numerous second generation antipsychotics have been introduced. Considering efficacy and safety profiles, how can we personalize treatment? What is the treatment approach for patients with predominant negative symptoms? People with schizophrenia often die prematurely. What are the factors that contribute to this higher mortality rate?

Highlights of EPA 2023

Professor Peter Falkai, past president of the European Psychiatric Association, is sharing his insights on the EPA 2023 Congress, guided by the motto “Social Cohesion, a Common Goal for Psychiatry”. He discussed topics such as the role of loneliness in the development of mental illnesses, the impact of nutrition in the development and prevention of mental illness, as well as the most important novelties in the treatment of schizophrenia.

Novel Pharmacotherapeutic Strategies for Regaining Control over Alcohol Intake in Alcohol Use Disorder

Prof. Benjamin Rolland give us a summary of the session, the most important messages.

Meeting the challenges of schizophrenia care during the COVID-19 pandemic

Prof. Silvana Galderisi speaks about how big is the burden of COVID-19 on patients with schizophrenia. What are the greatest challenges for physicians and care givers?

Consequences of COVID-19 Outbreak on Mental Health

Prof. Celso Arango speaks about the lessons he learned from coronavirus health crisis in Spain. He shares the most important findings and messages of his presentation.

Obstetric Complications: The Forgotten Risk Factor for Schizophrenia

Birth Asphyxia: Is this an area of primary pevention in schizophrenia? Prof. Robin Murray speaks about the most important findings of his presentation.

Difficult to Treat Depression

Prof. Andrea Fiorillo speaks about the newest novelties on the treatment of depression.

Consequences of COVID-19 Outbreak on Mental Health

Prof. Axel Börsch-Supan speaks about the most important findings of the Survey of Health, Ageing and Retirement in Europe (SHARE).

Highlights of the EPA 2021

Prof. Peter Falkai, the newly elected President of EPA summarize the highlights of the recent congress.

Antipsychotic treatment: polypharmacy is better than monotherapy – PRO